<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">493</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-1-162-167</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">A rare case of nodular lymphocyte predominant Hodgkin lymphoma, which developed 5 years after successful treatment of diffuse large B-cell lymphoma</article-title><trans-title-group xml:lang="ru"><trans-title>Редкий случай нодулярной лимфомы Ходжкина с лимфоцитарным преобладанием, развившейся через 5 лет после успешного лечения диффузной крупноклеточной В-клеточной лимфомы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9921-5620</contrib-id><name-alternatives><name xml:lang="en"><surname>Senchenko</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Сенченко</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow </p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3664-2876</contrib-id><name-alternatives><name xml:lang="en"><surname>Abramov</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Абрамов</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, pathologist, Pathology Department,</p><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>врач-патологоанатом патологоанатомического отделения,</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><email>dmitry.abramov@fccho-moscow.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rudneva</surname><given-names>A. E.</given-names></name><name xml:lang="ru"><surname>Руднева</surname><given-names>А. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow </p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2574-1636</contrib-id><name-alternatives><name xml:lang="en"><surname>Volchkov</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Волчков</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow </p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4978-0496</contrib-id><name-alternatives><name xml:lang="en"><surname>Nasirdinova</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Насирдинова</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow </p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gobadze</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Гобадзе</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow </p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4779-1896</contrib-id><name-alternatives><name xml:lang="en"><surname>Myakova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Мякова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow </p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7732-8184</contrib-id><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>D. M.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>Д. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-04-21" publication-format="electronic"><day>21</day><month>04</month><year>2021</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>162</fpage><lpage>167</lpage><history><date date-type="received" iso-8601-date="2021-04-20"><day>20</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-04-20"><day>20</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/493">https://hemoncim.com/jour/article/view/493</self-uri><abstract xml:lang="en"><p>Nodular lymphocyte predominant Hodgkin lymphoma (NLHLP) – B-cell lymphoma, which has been historically added to the group of Hodgkin's lymphomas, despite the peculiarities of the clinical course, treatment and prognosis, as well as morphological and immunophenotypical differences. In 75% of cases, the disease is detected at early stages (I–II according to Ann Arbor classification), has an indolent course and a favorable prognosis with 10-years an overall survival rate, more than 80%. Despite this, with long-term follow-up and the development of frequent relapses, transformation into diffuse large-cell B-cell lymphoma (DCBCL) or T-lymphocyte/histiocyte-rich DCBCL can occur, isolated cases in children. In the world literature, there are isolated cases of the development of NLHLP after treatment of DCBKL in adults, while among the pediatric population, cases have not been described. This article presents a clinical case of DCBKL in a 10-year-old child who, 5 years after the end of treatment, developed nodular Hodgkin's lymphoma with lymphocytic predominance. The patient's parents agreed to use the information, including the child's photo, in scientific research and publications. </p></abstract><trans-abstract xml:lang="ru"><p>Нодулярная лимфома Ходжкина с лимфоцитарным преобладанием (НЛХЛП) – В-клеточная лимфома, которая исторически отнесена в группу ходжкинских лимфом, несмотря на особенности клинического течения, лечения и прогноза, а также заметные морфологические, иммуногистохимические отличия от классической лимфомы Ходжкина. В 75% случаев заболевание выявляется на ранних стадиях (I–II по Ann Arbor), имеет индолентное течение и благоприятный прогноз с общей 10-летней выживаемостью &gt; 80%. Несмотря на это, при длительном наблюдении и развитии частых рецидивов может возникать трансформация в диффузную крупноклеточную В-клеточную лимфому (ДКБКЛ) или богатую Т-лимфоцитами/гистиоцитами ДКБКЛ, описаны единичные случаи у детей. В мировой литературе представлены единичные случаи развития НЛХЛП после лечения ДКБКЛ у взрослых, тогда как в детской популяции аналогичных случаев не описано. В данной статье представлен клинический случай ДКБКЛ у ребенка 10 лет, у которого через 5 лет после окончания лечения развилась НЛХЛП. Родители пациента дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях. </p></trans-abstract><kwd-group xml:lang="en"><kwd>Hodgkin's lymphoma</kwd><kwd>nodular lymphocytic-predominant Hodgkin's lymphoma</kwd><kwd>childhood lymphomas</kwd><kwd>lymphoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфома Ходжкина</kwd><kwd>нодулярная лимфома Ходжкина с лимфоцитарным преобладанием</kwd><kwd>лимфомы у детей</kwd><kwd>лимфома</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Swerdlow S.H., Campo E., Harris N.L. World Health Organization classification of haematopoetic and lymphoidt issues. Lyon: IARC Press; 2017. Рp. 323–5.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nogová L., Reineke T., Brillant C., Sieniawski M., Rüdiger T., Josting A., et al.; German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26 (3): 434–9. DOI: 10.1200/JCO.2007.11.8869</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Xing K.H., Connors J.M., Mansour M.A., Gascoyne R.D. The outcome of advanced stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) compared to classical Hodgkin lymphoma (CHL): a matched pair analysis. ASH Annual Meeting 2012 (abstract 1531)</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Biasoli I., Stamatoullas A., Meignin V., Delmer A., Reman O., Brice P., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diff use large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116 (3): 631–9. DOI: 10.1002/cncr.24819</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D., Shankar A., Dörffel W., Wallace W.H., et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110 (1): 179–85.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Couronné L., Schneider P., Picquenot J.M., Laberge S., Bastard C., Vannier J.P. Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 2008; 30 (12): 959–62. DOI: 10.1097/MPH.0b013e31818a9564</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Fan Z., Natkunam Y., Bair E., Tibshirani R., Warnke R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27 (10): 1346–56. DOI: 10.1097/PAS.0b013e318165b0d6</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Rudiger T., Gascoyne R.D., Jaff e E.S., de Jong D., Delabie J., Müller-Hermelink H.K., et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13 Suppl 1: 44–51. DOI: 10.1093/annonc/13.s1.44</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mauz-Körholz C., Lange T., Hasenclever D., Burkhardt B., Feller A.C., Dörffel W., et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr 2015; 227 (6–7): 314–21. DOI: 10.1055/s-0035-1559664</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Xu-Monette Z.Y., Li J., Xia Y., Crossley B., Bremel R.D., Miao Y., et al. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune check point blockade and neoantigen-based immunotherapies. J Immunother Cancer 2019; 7 (1): 272. DOI: 10.1186/s40425-019-0730-x</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dunn-Walters D., Thiede C., Alpen B., Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001; 356 (1405): 73–82. DOI: 10.1098/rstb.2000.0751</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Koh K.N., Yoo K.H., Im H.J., Sung K.W., Koo H.H., Kim H.S. et al. Characteristics and Outcomes of Second Malignant Neoplasms after Childhood Cancer Treatment: Multi-Center Retrospective Survey. J Korean Med Sci 2016; 31 (8): 1254–61. DOI: 10.3346/jkms.2016.31.8.1254</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Fianchi L., Pagano L., Piciocchi A., Candoni A., Gaidano G., Breccia M., et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90 (5): E80–5. DOI: 10.1002/ajh.23966</mixed-citation></ref></ref-list></back></article>
